Zilucoplan Market

The market for Zilucoplan was estimated at $245 million in 2025; it is anticipated to increase to $568 million by 2030, with projections indicating growth to around $1.32 billion by 2035.

Report ID:DS1802040

Author:Debadatta Patel - Senior Consultant

Published Date:March 2025

Datatree

Life Science

Pharmaceutical

Zilucoplan

Customization Available

Zilucoplan - 2025-2035

Market Outlook
Market Key Insights
Growth Opportunity
Market Dynamics
Application
Recent Development
Impact Analysis

Report Summary

Market Data

Methodology

Table of Contents

Report Summary

Market Data

Methodology

Table of Contents

Global Zilucoplan Market Outlook

Revenue, 2025

$245M

Forecast, 2035

$1.32B

CAGR, 2026 - 2035

18.3%

The Zilucoplan industry revenue is expected to be around $290.1 million in 2026 and expected to showcase growth with 18.3% CAGR between 2026 and 2035. With this strong foundation in place, the market for Zilucoplan is poised to be a leading aspect of the treatment of complex autoimmune diseases; it is driven by the growing prevalence of diseases which affect nerves and muscles, and also by an increased diagnosis rate and the clinical focus on the blocking of the complement system. Across the majority of hospitals and specialist clinics, there has been significant interest in this product. This demonstrates the product is integrated into the most critical care processes and suggests a long term need for this product across the most important markets. The market leading 23 mg dosage formulation generated $93.55 billion by 2025, indicating the confidence that doctors have in the safety and effectiveness of this treatment, thus matching the insurance preference for treatments for myasthenia gravis that are standardised and scientifically supported. A range of supportive factors, including beneficial payment schemes, continued monitoring of treatments after they have been released and partnerships between biotech firms and medical specialists, have helped to keep Zilucoplan a major player in its region of the market.

With a unique mechanism of action as a complement C5 inhibitor, zilucoplan is intended for the precise modulation of the complement system. This will be achieved through once daily injections of the drug under the skin, thereby improving the patients compliance to treatment. Characteristics include rapid clinical improvement and a durable response, a targeted action mechanism that reduces general immunosuppression, and an ability to be used in conjunction with other treatments for generalised myasthenia gravis and various other conditions of neuromuscular system which are complement mediated. The main uses of this therapy at present are for patients who have conditions that make it difficult for their bodies to heal, and also for people who suffer from severe cases of various conditions. It is also being researched for use in more widespread autoimmune diseases and in rare conditions. The growing field of complement pathway inhibitors is driven by new trends in the market, such as expansion of label indications, more frequent guideline adoption, and an accumulation of evidence from real world data showing the long term benefits. This places Zilucoplan at the forefront in this emerging class of drugs.

Zilucoplan market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035 — Zilucoplan Market Outlook

Market Key Insights

The Zilucoplan market is projected to grow from $245.2 million in 2025 to $1.32 billion in 2035. This represents a CAGR of 18.3%, reflecting rising demand across Myasthenia Gravis Treatment, Immune-mediated Nephrotic Syndrome Therapy, and Paroxysmal Nocturnal Hemoglobinuria Management.
UCB S.A. Belgium is the sole producer in this market, holding full control over supply and pricing.
U.S. and Japan are the top markets within the Zilucoplan market and are expected to observe the growth CAGR of 17.6% to 25.6% between 2025 and 2030.
Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 13.7% to 19.0%.
The complete eco-system of the Zilucoplan market is becoming more attractive for investment due to transitions such as Shift Towards Personalized Medicine. These changes are expected to create a positive cycle that supports growth and adds an estimated $41 million in value between 2026 and 2030.
The Zilucoplan market is set to add $1.1 billion between 2025 and 2035, with manufacturer targeting Off-label Use Application projected to gain a larger market share.
With
rising prevalence of complement‑mediated diseases and patient preference for self‑administered therapies, and
Orphan drug designation and regulatory exclusivity supporting market expansion, Zilucoplan market to expand 437% between 2025 and 2035.

Zilucoplan - Country Share Analysis

Opportunities in the Zilucoplan

In the Asia Pacific, there is also growing interest in the administration of zilucoplan injections for young patients with chronic inflammatory and neuromuscular diseases. Healthcare payers and treatment providers are seeking therapies that reduce congestion at infusion centres and enable the use of digital tools to monitor patients adherence to treatment. Even with a strength of 32.4 milligrams, those requiring a high dose can use it at home. The market size of this 32.4 mg segment is forecast to grow at the fastest compound annual growth rate during the forecast period globally, rising from $36.61 billion in 2025 to $141.37 billion by 2030.

Growth Opportunities in North America and Europe

The Zilucoplan market in North America is primarily driven by strong neurologist awareness, high diagnostic rates for myasthenia gravis and the flexibility offered by subcutaneous injections, with the clinics specialising in neuromuscular disorders having the most influence. The main region's to focus on are the positioning of Zilucoplan as the best future complement inhibitor for neuromuscular conditions, expanding home care services and using digital tools to encourage medication adherence. The main competition in this market comes from established treatments for myasthenia gravis which have a strong brand and extensive range of neurologic treatments. Zilucoplan must differentiate itself with the benefits it offers to patients in terms of convenience, health and quality of life.

In the EU, where healthcare is centrally organised, healthcare technology is rigorously assessed before it is accepted and a set of guidelines exists for the treatment of myasthenia gravis. Large hospitals are responsible for treating patients in the early stages of myasthenia gravis and in complicated cases, while specialist clinics are the places where patients with the condition go for ongoing treatment. Reimbursing Zilucoplan could be made easier if it is marketed as a treatment for a rare disease and its benefits are highlighted, doctors could be given structured treatment pathways for patients and the possibility of patients being treated at home could be looked at where the rules permit this. It is very likely that Zilucoplan will struggle to gain market share as a result of the existence of already established treatments for myasthenia gravis and the fact that the healthcare systems in Europe are now under a lot of pressure financially. Zilucoplan will be successful in the long term if its target market is clearly defined, the various stages of a patients treatment are carefully managed and partnerships with other healthcare providers are formed.

Market Dynamics and Supply Chain

Driver: Rising prevalence of complement‑mediated diseases and patient preference for self‑administered therapies

Growing awareness and diagnosis of complement‑mediated conditions like generalized myasthenia gravis (gMG) have also expanded demand for targeted inhibitors. Zilucoplan’s subcutaneous infusion, once‑daily self‑administration aligns with patient preferences for at‑home treatment options, reducing hospital visits and healthcare burden. At the same time, healthcare systems are also emphasizing value‑based care, favoring therapies that improve quality of life and adherence. This trend benefits products like Zilucoplan over traditional intravenous options that require infusion centers. Additionally, increasing investments in rare disease research and orphan drug incentives have also accelerated innovation and market entry for complement inhibitors, further driving adoption. The combined effect of unmet medical needs and patient‑centric delivery models underpins robust uptake in neuromuscular indications.

Zilucoplan’s orphan status enhances its competitive edge by securing extended market exclusivity and facilitating expedited regulatory pathways. These incentives encourage investment in clinical development and distribution infrastructure, supporting broader access in rare disease populations.

Restraint: Regulatory Challenges

In the sector where Zilucoplan operates in the market space is obligated to adhere to strict regulations worldwide that greatly influence how its products are developed and brought to consumers attention effectively and safely. Zilucoplan being a medication faces an arduous journey towards gaining approval from regulatory agencies such, as the FDA and EMA. These stringent rules require clinical studies and extensive safety evaluations which not only prolong the time it takes for the product to reach the market but also escalate the overall costs of development. These various factors undoubtedly impact Zilucoplans ability to expand its market presence.

Opportunity: Untapped European demand for Zilucoplan in neuromuscular autoimmune diseases and home-based care and Expanding Zilucoplan use for generalized myasthenia gravis in United States neuroimmunology centers

With its approved use in Europe, Sanofis Zilucoplan has the potential to fill gaps in the treatment of rare autoimmune diseases of the nervous system and muscles. Patients with overlapping health conditions are often not only given the treatment they require, due to a lack of integration between care provided at home and in hospitals where biologics are dispensed. A treatment regimen for zilucoplan which involves injections under the skin allows for dosages of 16.6 mg and self medication by patients, this matches the evolving preferences of those who pay for the treatment. By 2030, it is predicted that rare disease treatments available in 16.6 mg strength will have a worth of $207.42 billion. In the year 2025, this strength of treatments will be worth $63.53 billion.

Care for the condition myasthenia gravis is undergoing change because of increasing awareness of the drug Zilucoplan as a C5 complement inhibitor. Individuals with seronegative rheumatoid arthritis, who dont improve with various medications, could also gain from alternative drugs that are presently not only being tried. Given an emphasis on treatment regimens which are patient administered via injections, plus other self management options, health authorities recommend a stable dosage of 23 mg for patients being treated as outpatients. Over the next five years the market is predicted to grow to $311.51 billion in 2030 from $93.55 billion in 2025 driven by the USA market demand.

Challenge: Competition from established intravenous complement inhibitors and adherence challenges

Despite self‑administration benefits, zilucoplan faces strong competition from long‑acting intravenous C5 inhibitors like eculizumab and ravulizumab that have entrenched prescriber familiarity and proven efficacy across multiple indications. These competitors can reduce the market share for zilucoplan, especially in settings where infusion logistics are preferred or insurance coverage favors long‑interval dosing, impacting demand dynamics.

Supply Chain Landscape

C5 Inhibitor API

BachemPolyPeptide GroupCordenPharma

Zilucoplan Injection Manufacturing

UCB IncCatalent

Cold Chain Distribution

McKessonCardinal HealthCencora

Patient Treatment Settings

HospitalsNeurology clinicsMyasthenia gravis centers

C5 Inhibitor API

BachemPolyPeptide GroupCordenPharma

Zilucoplan Injection Manufacturing

UCB IncCatalent

Cold Chain Distribution

McKessonCardinal HealthCencora

Patient Treatment Settings

HospitalsNeurology clinicsMyasthenia gravis centers

Zilucoplan - Supply Chain

Use Cases of Zilucoplan in Myasthenia Gravis Treatment & Paroxysmal Nocturnal Hemoglobinuria Management

Myasthenia Gravis Treatment : Zilucoplan, a selective complement C5 inhibitor administered as a once‑daily subcutaneous peptide injection, is mainly used by adult patients with acetylcholine receptor antibody‑positive generalized myasthenia gravis to reduce immune‑mediated neuromuscular junction damage and improve muscle strength. Zilbrysq, marketed by UCB, stands out for its self‑administration and convenience compared with intravenous therapies, enhancing outpatient adherence. UCB’s strong orphan drug positioning and specialty pharmacy distribution strengthen its market presence against IV C5 inhibitors like Soliris and Ultomiris.

Immune-mediated Nephrotic Syndrome Therapy : Although clinical development explored zilucoplan for immune‑mediated nephrotic syndrome due to its C5 complement inhibition, targeting pathological complement activation in renal tissue, this application remains investigational and was not advanced to approval. Zilucoplan’s mechanism could theoretically reduce proteinuria by dampening complement‑driven glomerular injury, but lack of regulatory endorsement and limited late‑stage data constrain its use. Established nephrology competitors focus on other complement pathway targets with approved indications, underscoring current gaps in this segment.

Paroxysmal Nocturnal Hemoglobinuria Management : Zilucoplan was evaluated in phase 2 trials for PNH based on its ability to block complement C5 and reduce hemolysis, but clinical development in this indication was discontinued. As a small macrocyclic peptide, zilucoplan showed some reduction in hemolysis markers in early studies, yet it did not progress to approval. In the PNH market, established C5 inhibitors such as eculizumab (Soliris) and ravulizumab (Ultomiris) dominate due to robust clinical evidence and regulatory leadership.

Recent Developments

Recent strategic developments for Zilucoplan highlight its expanding complement C5 inhibitor role in neuromuscular care and global rare disease markets. UCB’s Zilbrysq has achieved regulatory approvals in key regions, including China, Canada, and South Korea, broadening access for adult gMG patients and boosting specialty pharmacy distribution. Ongoing presentations of real‑world and long‑term efficacy data at major neurology congresses reinforce physician confidence and treatment adoption. The key market trend is the shift toward self‑administered subcutaneous therapies that improve patient autonomy and support decentralized care models in autoimmune diseases.

December 2024 : ZILBRYSQ (zilucoplan) became commercially available in the United States by prescription for adult patients with generalized myasthenia gravis (gMG) who are anti‑acetylcholine receptor antibody positive, with distribution through UCB’s selected exclusive specialty pharmacy and required REMS enrollment due to safety considerations.

October 2024 : The European Commission granted marketing authorization for ZILBRYSQ (zilucoplan) as an add‑on to standard therapy for the treatment of adult generalized myasthenia gravis patients who are anti‑AChR antibody‑positive, expanding UCB’s global regulatory footprint following approvals in the U.S. and Japan.

Impact of Industry Transitions on the Zilucoplan Market

As a core segment of the Pharmaceutical industry, the Zilucoplan market develops in line with broader industry shifts. Over recent years, transitions such as Shift Towards Personalized Medicine and Evolving complement inhibition landscape have redefined priorities across the Pharmaceutical sector, influencing how the Zilucoplan market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

Shift Towards Personalized Medicine

Personalised treatments are slowly becoming a norm in the treatment of Myasthenia Gravis and other autoimmune diseases and are opening up new avenues for Zilucoplan. However, the key players in this market are adopting data analysis tools and big data slowly. This is affecting Zilucoplans lead in this field. This widening gap in execution is also opening up an increasing revenue opportunity for other biologic medicines, which include the complement inhibitors Eculizumab and Ravulizumab Injection. The use of these is being developed in hospitals and clinics that specialise in a particular region. These targeted therapy alternatives will dominate the existing Zilucoplan market which is projected to be worth $58 billion in the chronic disease digital therapeutics and individualised care sectors. This development will significantly change the long term dynamics of market share and increase the risks faced by companies that develop late acting Zilucoplan treatments.

Evolving complement inhibition landscape

Complement pathway modulation is becoming a focus across therapeutic areas, driving innovation beyond traditional monoclonal antibodies. Zilucoplan’s macrocyclic peptide structure exemplifies this transition, enabling rapid onset of action and potentially broader tissue penetration. Although its development in indications beyond gMG was discontinued, the platform demonstrates how complement inhibition strategies are diversifying. Competitors are exploring small molecules, dual pathway inhibitors, and oral agents, reshaping treatment paradigms for rare immunological and hematological diseases, and influencing future research investments.